The expiration for the patent of the new formulation of Prozac, also known as the generic drug Fluoxetine Hydrochloride, is slated for November 1, 2017. As a common and effectual antidepressant, Fluoxetine HCl CAS# 56296-78-7, has proven to be a valuable treatment for patients in the United States and worldwide. In fact, antidepressant use in general has risen by 400% between 1988–1994 and 2005–2008. This astronomical increase was released in a report in October of 2011, from the National Center for Health Statistics, based on the rate of antidepressant use in the U.S. among teens and adults ages 12 and older. In addition, the National Health and Nutrition Examination Survey revealed that antidepressants were the third most common prescription medication taken by Americans in the years 2005–2008. What makes the newest version of Eli Lilly’s Prozac unique is that it is a once a week dosing schedule, making administration of this antidepressant easier and convenient. Patients will appreciate this once weekly 90 milligram dose, which is in a delayed release capsule. As the rate of antidepressant users grows at a phenomenal rate, the advent of a once a week treatment for depression is not only useful, but it is also needed.
Fluoxetine has been touted in the news lately as more than meets the eye. A study published in Neuropsychopharmacology in January 2013 revealed that Fluoxetine may be involved in creating new brain cells. As a widely used antidepressant researchers attempted to stimulate the production of new neurons from L1-INP cells. The L1-INP cells are progeny nerve cells that exist at the surface of the adult cortex. A lack of blood, also known as ischemia, enhances the generation of new inhibitory neurons from these neural progenitor cells. Coined L1-INP from the name “Layer 1 Inhibitory Neuron Progenitor cells”, scientists were initially unsure if L1-INP-related neurogenesis could be induced in the normal adult cortex. Through the research and investigation scientists discovered that a large percentage of the newly generated neurons were indeed inhibitory GABAergic interneurons. The generation of these interneurons coincided with a reduction in cell death following ischemia. Results were gleaned in favor of Fluoxetine, with researchers finding that this selective serotonin reuptake inhibitor has a neuroprotective response. Fluoxetine was found to aid in the purposeful creation of new nerve cells in the brain, which in turn helps to treat and prevent both neurodegenerative diseases and psychiatric disorders. LGM Pharma provides API and TEVA API Fluoxetine for research and development purposes.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.